Inventor · Paris, FR

Claude Leclerc

26Patents
6h-index
42Co-inventors
69Inventor score

Filing activity: Nov 7, 1994 → Feb 28, 2017

Most-cited inventions

PatentTitleAreaCited byStatus
US5871747A Antigen-carrying microparticles and their use in the indication of humoral or cellular responses Emerging Cross-Sectional Technologies 116 Expired
US6004763A Antigen-carrying microparticles and their use in the induction of humoral or cellular responses Emerging Cross-Sectional Technologies 49 Expired
US5503829A Recombinant mutants for inducing specific immune responses Emerging Cross-Sectional Technologies 17 Expired
US5935580A Recombinant mutants for inducing specific immune responses Emerging Cross-Sectional Technologies 12 Expired
US6676946B2 Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof Emerging Cross-Sectional Technologies 10 Expired
US8628779B2 Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof Chemistry; Metallurgy 6 Active
US5679784A Recombinant mutants for inducing specific immune responses Emerging Cross-Sectional Technologies 6 Expired
US8747866B2 Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti Human Necessities 5 Active
US7906123B1 Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof Human Necessities 4 Active
US8017132B2 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell Emerging Cross-Sectional Technologies 4 Active
US8637039B2 Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof Chemistry; Metallurgy 4 Active
US9095537B2 Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response Chemistry; Metallurgy 3 Active
US9410139B2 Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens Mechanical Engineering; Lighting; Heating 2 Active
US6458362B1 Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes Emerging Cross-Sectional Technologies 2 Expired
US9370564B2 Vectors for molecule delivery to CD11b expressing cells Emerging Cross-Sectional Technologies 1 Active
US9957301B2 Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response Chemistry; Metallurgy 1 Active
US8398991B2 Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG Chemistry; Metallurgy 1 Active
US9155783B2 Agents and methods based on the use of the EDA domain of fibronectin Emerging Cross-Sectional Technologies 0 Active
US10004794B2 Vectors for molecule delivery to CD11b expressing cells Emerging Cross-Sectional Technologies 0 Active
US9387243B2 Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof Chemistry; Metallurgy 0 Active
US9222143B2 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell Chemistry; Metallurgy 0 Active
US7696326B2 Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof Emerging Cross-Sectional Technologies 0 Active
US7883712B2 Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti Human Necessities 0 Active
US9708596B2 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell Chemistry; Metallurgy 0 Active
US9657074B2 Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof Human Necessities 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.